Zobrazeno 1 - 10 of 119 pro vyhledávání: '"Viola W, Zhu"'
1
Akademický článek
The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study
Autor: David J. Benjamin, MD, Shuai Chen, PhD, Joanna B. Eldredge, MD, Shiruyeh Schokrpur, MD, Debory Li, Zhikuan Quan, MS, Jason W. Chan, MD, Amy L. Cummings, MD, Megan E. Daly, MD, Jonathan W. Goldman, MD, Matthew A. Gubens, MD, Jeremy P. Harris, MD, Mark W. Onaitis, MD, Viola W. Zhu, MD, PhD, Sandip P. Patel, MD, Karen Kelly, MD
Publikováno v: JTO Clinical and Research Reports, Vol 3, Iss 12, Pp 100427- (2022)
Introduction: There is a paucity of data on immune checkpoint inhibitors (ICIs) plus doublet chemotherapy (C) in patients with advanced lung cancer whose tumor harbors an actionable mutation. We sought to provide insight into the role of this combina
Externí odkaz: https://doaj.org/article/3801fd9322224ff8af798db8607d43fe
Zobrazit plný text záznamu
2
Akademický článek
Will the clinical development of 4th-generation 'double mutant active' ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK+ NSCLC?
Autor: Sai-Hong Ignatius Ou, Misako Nagasaka, Danielle Brazel, Yujie Hou, Viola W. Zhu
Publikováno v: Translational Oncology, Vol 14, Iss 11, Pp 101191- (2021)
Our current treatment paradigm of advanced anaplastic lymphoma kinase fusion (ALK+) non-small cell lung cancer (NSCLC) classifies the six currently approved ALK tyrosine kinase inhibitors (TKIs) into three generations. The 2nd-generation (2G) and 3rd
Externí odkaz: https://doaj.org/article/18fb6cf323bc4f85acc645832047fa60
Zobrazit plný text záznamu
3
Akademický článek
Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers
Autor: Noura J. Choudhury, MD, Jaime L. Schneider, MD, PhD, Tejas Patil, MD, Viola W. Zhu, MD, PhD, Debra A. Goldman, MS, Soo-Ryum Yang, MD, Christina J. Falcon, MPH, Andrew Do, BS, Yunan Nie, MD, Andrew J. Plodkowski, MD, Jamie E. Chaft, MD, Subba R. Digumarthy, MD, Natasha Rekhtman, MD, PhD, Maria E. Arcila, MD, Alexia Iasonos, PhD, Sai-Hong I. Ou, MD, PhD, Jessica J. Lin, MD, Alexander Drilon, MD
Publikováno v: JTO Clinical and Research Reports, Vol 2, Iss 7, Pp 100187- (2021)
Introduction: ROS1 fusions are oncogenic drivers in 1% to 3% of NSCLCs. The activity of immune checkpoint inhibitor (ICI) monotherapy or in combination with chemotherapy (chemotherapy with ICI [chemo-ICI]) in these tumors and their immunophenotype ha
Externí odkaz: https://doaj.org/article/81bc0a6f5dc849f182e47505ceaaaec1
Zobrazit plný text záznamu
4
Akademický článek
Identification of Novel CDH1-NRG2α and F11R-NRG2α Fusions in NSCLC Plus Additional Novel NRG2α Fusions in Other Solid Tumors by Whole Transcriptome Sequencing
Autor: Sai-Hong Ignatius Ou, MD, PhD, Joanne Xiu, PhD, Misako Nagasaka, MD, Bing Xia, MD, Shannon S. Zhang, MD, Qing Zhang, PhD, Jeffrey J. Swensen, PhD, David Spetzler, MS, PhD, MBA, Wolfgang Michael Korn, MD, Viola W. Zhu, MD, PhD, Stephen V. Liu, MD
Publikováno v: JTO Clinical and Research Reports, Vol 2, Iss 2, Pp 100132- (2021)
Introduction: A novel CD74-NRG2α fusion has recently been identified in NSCLC. We surveyed a large tumor database comprehensively profiled by whole transcriptome sequencing to investigate the incidence and distribution of NRG2 fusions among various
Externí odkaz: https://doaj.org/article/ac0c0482fe5145d4bdb2310e09e643cc
Zobrazit plný text záznamu
5
Akademický článek
A Novel Sequentially Evolved EML4-ALK Variant 3 G1202R/S1206Y Double Mutation In Cis Confers Resistance to Lorlatinib: A Brief Report and Literature Review
Autor: Viola W. Zhu, MD, PhD, Misako Nagasaka, MD, Russell Madison, BA, Alexa B. Schrock, PhD, Jean Cui, PhD, Sai-Hong Ignatius Ou, MD, PhD
Publikováno v: JTO Clinical and Research Reports, Vol 2, Iss 1, Pp 100116- (2021)
Lorlatinib is a third-generation ALK inhibitor that can overcome the largest number of acquired ALK resistance mutations, including the solvent-front mutation G1202R. Here, we report, for the first time, a novel, sequentially-evolved EML4-ALK variant
Externí odkaz: https://doaj.org/article/0f88699f4ca44685b12f532982b48a21
Zobrazit plný text záznamu
6
Akademický článek
Catalog of 5′ fusion partners in RET+ NSCLC Circa 2020
Autor: Sai-Hong Ignatius Ou, MD, PhD, Viola W. Zhu, MD, PhD
Publikováno v: JTO Clinical and Research Reports, Vol 1, Iss 2, Pp 100037- (2020)
Since the discovery of RET fusion–positive (RET+) NSCLC around late 2011 to early 2012, clinical trials of multikinase inhibitors and highly potent and selective RET tyrosine kinase inhibitors have indicated that RET fusion is an actionable oncogen
Externí odkaz: https://doaj.org/article/4bf386fea8fb4953a9d2f91c6ef4706f
Zobrazit plný text záznamu
7
Akademický článek
Catalog of 5’ Fusion Partners in ALK-positive NSCLC Circa 2020
Autor: Sai-Hong Ignatius Ou, MD, PhD, Viola W. Zhu, MD, PhD, Misako Nagasaka, MD
Publikováno v: JTO Clinical and Research Reports, Vol 1, Iss 1, Pp 100015- (2020)
Since the discovery of anaplastic lymphoma kinase fusion-positive (ALK+) NSCLC in 2007, the methods to detect ALK+ NSCLC have evolved and expanded from fluorescence in situ hybridization and immunohistochemistry to next-generation DNA sequencing, tar
Externí odkaz: https://doaj.org/article/555bb3db331e4ff1b1172ed1dc9a1871
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje